Breaking News, Collaborations & Alliances

XBiotech USA, CTA Sign License Agreement

For the advancement and the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7

XBiotech USA has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company.  Under the terms of the license agreement, XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7. Accordingly, XBiotech will now begin to establish the production capability to enable 12D7 clinical development.   The 12D7 antibody targets NY-ESO-1, a cancer-related protein commonly f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters